Asthma and chronic obstructive pulmonary disease (COPD) are chronic respiratory diseases that cause breathing difficulty and coughing. Both conditions share similar symptoms. Understanding their ...

Understanding the Context

New therapeutic 'cocktails' may provide long-lasting relief for treatment-resistant asthma and other immune system inflammatory diseases. Current asthma treatments don't work in all patients, and they ... A handful of North American companies which see potential for vape-like devices to ease migraines and respiratory diseases such as asthma have a long road to convince health authorities and patients ... Yahoo Finance: Kymera Therapeutics Announces U.S.

Key Insights

FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track ... Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma Yahoo Finance: Sanofi’s bispecific scores in respiratory diseases but fails in eczema clinicaladvisor.com: Can Changes in Diet Prevent Asthma or Affect the Disease Course?